News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

During the next phase of the adult observational study, RECOVER researchers will continue investigating the causes of autonomic dysfunction, with symptoms such as dizziness, rapid heart rate, and extreme fatigue.
RECOVER researchers continue to publish findings that could help scientists, doctors, patients, and caregivers navigate the complexities of Long COVID.
RECOVER researchers conducted a clinical trial to test whether PAXLOVID, an antiviral drug, could reduce Long COVID symptoms when taken for 15 or 25 days. The study enrolled 959 adults with Long COVID at 69 sites across the US.
In early 2027, RECOVER will launch the next phase of its pediatric study, following more than 4,300 children, teens, and young adults over 2 years to learn how Long COVID changes as they grow up.
Biosamples collected during RECOVER clinical trials can provide valuable information about how people’s bodies respond to treatment. Researchers who receive funding through a new research opportunity can now access these samples.
Drawing on lived experience, RECOVER Representatives created 4 new resources to help people with Long COVID track symptoms, navigate work, find mental health support, and access financial assistance.
NIH invites investigators to apply for a new research opportunity, which funds pathobiology studies. Applicants can request use of data and biosamples from RECOVER observational studies and, for the first time, RECOVER clinical trials.
RECOVER’s electronic health record study, which completed analyses in May, examined the health data of over 60 million people to advance Long COVID research.